×
About 25,665 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  7,179 results

Herpes Simplex Virus 1 Can Bypass Impaired Epidermal Barriers upon Ex Vivo Infection of...
https://doi.org/10.1128/jvi.00864-22
Journal of Virology; Möckel M, De La Cruz NC et. al.

Aug 16th, 2022 - To infect its human host, herpes simplex virus 1 (HSV-1) must overcome the protective barriers of skin and mucosa. Here, we addressed whether pathological skin conditions can facilitate viral entry via the skin surface and used ex vivo infection s...

Latest Combination Therapies in Psoriasis: Narrative Review of The Literature.
https://doi.org/10.1111/dth.15759
Dermatologic Therapy; Diotallevi F, Paolinelli M et. al.

Aug 13th, 2022 - Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always ...

State medicaid coverage of over-the-counter moisturizers: A cost-effective management s...
https://doi.org/10.1111/pde.15038
Pediatric Dermatology; Scollan ME, Garzon MC et. al.

Aug 13th, 2022 - Regular moisturizing with over-the-counter (OTC) treatments is considered a cornerstone of atopic dermatitis (AD) management regardless of disease severity, but OTC moisturizers are not an eligible product under most state Medicaid benefits, inclu...

Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study.
https://doi.org/10.1097/MD.0000000000029963
Medicine Hashimoto K, Nishimura S et. al.

Aug 13th, 2022 - There is no consensus on a treatment strategy for spinal giant cell tumor of bone (GCTB) because of the difficulty in their treatment. Treatment options often include the use of the controversial denosumab, an antibody therapy aimed at tumor shrin...

Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at t...
https://doi.org/10.1186/s12967-022-03566-6
Journal of Translational Medicine; Zhang D, Li Y et. al.

Aug 13th, 2022 - Approximately 8-9% of the world's population is affected by autoimmune diseases, and yet the mechanism of autoimmunity trigger is largely understudied. Two unique cell death modalities, ferroptosis and pyroptosis, provide a new perspective on the ...

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  506 results see all →

Clinicaltrials.gov  1,045 results

Allergic Disease Onset Prevention Study
https://clinicaltrials.gov/ct2/show/NCT05003804

Aug 12th, 2022 - This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subj...

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT05155085

Aug 12th, 2022 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with moderate-to-severe AD inadequately...

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children
https://clinicaltrials.gov/ct2/show/NCT04740892

Aug 12th, 2022 - The purpose of this study is to evaluate the effectiveness (assessed by clinical evaluation of eczema/atopic dermatitis severity and parent-perceived benefits) and tolerability (assessed by clinical grading and parent-perception) of the investigat...

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04773587

Aug 12th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
https://clinicaltrials.gov/ct2/show/NCT04836858

Aug 12th, 2022 - The main purpose of this phase 2 study is to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.

see more →

News  1,513 results

Dermatologists share vitiligo breakthrough news with patients
https://www.mdedge.com/dermatology/article/257010/pigmentation-disorders/dermatologists-share-vitiligo-breakthrough-news
Marcia Frellick

Aug 12th, 2022 - For the first time, patients with vitiligo who have long lived with patches of skin that are without pigment can now have even skin tones on their faces and other bodily regions with a Food and Drug Administration–approved, easy-to-use topical tre.

Dupilumab Dose Reduction Successful in Controlled Atopic Dermatitis
https://www.medscape.com/viewarticle/979120

Aug 12th, 2022 - Dupilumab dose reduction appears feasible in patients with controlled atopic dermatitis (AD) who have been on the monoclonal antibody therapy for at least 1 year, according to a recent study. The researchers suggest that the findings, published in...

'I Shall Harm': When Patients Experience the Nocebo Effect
https://www.medscape.com/viewarticle/979130

Aug 12th, 2022 - I was quite sure I had multiple sclerosis when I was a medical student. I first noticed symptoms during my neurology rotation. All the signs were there: Fatigue that was getting worse in the North Carolina heat (Uhthoff sign!). A tingle running do...

Baricitinib Reduces Signs and Symptoms of Cyclosporine-Resistant AD Up to 1 Year
https://www.medscape.com/viewarticle/979094

Aug 11th, 2022 - The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) improves signs and symptoms of moderate to severe atopic dermatitis (AD) in patients who fail or cannot tolerate cyclosporine, according to a phase 3 study published in the British Journ...

Commentary: Conditions Associated with AD, August 2022
https://www.mdedge.com/dermatology/article/256875/atopic-dermatitis/commentary-conditions-associated-ad-august-2022
Jonathan Silverberg, MD, PhD, MPH

Aug 8th, 2022 - Jonathan Silverberg, MD, PhD, MPH Atopic dermatitis (AD) is truly a fascinating disease! Despite the thousands of scientific manuscripts published on AD, more novel insights keep coming about the clinical manifestations and risk factors of this co.

see more →

Patient Education  14 results see all →